Jagsonpal Pharmaceuticals Limited — Important, 06-05-2026: Updates

Jagsonpal Pharmaceuticals announces a buyback of 16 Lakh shares at ₹250 each, totaling ₹40 Cr. This offers a premium of ~40-48% over recent market prices. Promoters won't participate, potentially increasing public shareholder stake. The debt-free company aims to return surplus cash, enhance ROE/EPS, leveraging strong cash flows and asset-light model. Shareholder gains are now taxable as capital gains, plus STT.